Loading…
Prescription Drug Affordability Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
58pct
8d open
vs 6,490 other HR bills in the 111th — cohort avg 44d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2010 · fourth_quarter · Medicare/Medicaid
Bills with similar content found using semantic analysis.
Sources: Congress.gov
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 1232 and S. 80, In support of Medicare Part D Improvement: S. 266 and H.R. 3418, In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975 and H.R. 2417
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Pharmacy
S 256/HR 2923 - Combat Methamphetamine Enhancement Act of 2010 S 3397/ HR 1359 - Secure and Responsible Drug Disposal Act of 2010 HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 Under Line 17: We would like to include the Office of National Drug Control Policy (ONDCP) HR 5710 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010 HAMDT 740 (to HR 5822 Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2010) - a VA prescription drug re-labeling program HR 1204 - The Community Pharmacy Fairness Act of 2009 S 754 - The Methadone Treatment and Protection Act of 2009 HR 2855 - The Drug Overdose Reduction Act HR 163 - Prescription Drug Affordability Act S 80 - Pharmaceutical Market Access Act of 2009 HR 3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps (Docket Number: FDA-2010-N-0001) Third Annual Sentinel Initiative Public Workshop (Docket Number: FDA-2010-N-0128) Prescription Drug User Fee Act; Reopening of the Comment Period (Docket Number: FRL-9197-7) EPA Best Management Practices for Unused Pharmaceuticals at Health Care Facilities (Docket Number: FDA2010N0128) Prescription Drug User Fee Act; Meetings on Reauthorization; Public Meetings (Docket Number FDA-2010-N-0284 and 2009-D-0461) Risk Evaluation and Mitigation Strategies; Notice of Public Meeting; Reopening of Comment Period (Docket Number: DEA-338) Schedules of Controlled Substances: Placement of Propofol Into Schedule IV; Proposed Rule (Docket Number: FDA-2010-N-0273) Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Quality System Regulations (Docket No. FDA-2010-N-0344) Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Testing Communications on Medical Devices and Radiation-Emitting Products (Docket Number: FDA2010N0437) Development and Distribution of Patient Medication Information for Prescription Drugs; Public Hearing (Docket Number: FDA-2010-N-0477) Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments (Docket Number: FDA2010N0486) Safe Use Initiative; Public Workshop; Request for Comments (RIN 0720AB45) DoD Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/ TRICARE: Inclusion of TRICARE Retail Pharmacy Program in Federal Procurement of Pharmaceuticals (Docket Number: DEA316N) Procedures for the Surrender of Unwanted Controlled Substances by Ultimate Users; Notice of Meeting (Docket Number: DEA 337N) Dispensing of Controlled Substances at Long-Term Care Facilities; Notice, Solicitation of Information (Docket Number: DEA-339S) Role of Authorized Agents in Communicating Controlled Substance Prescriptions to Pharmacies FDA Draft Guidance for Industry and Food and Drug Administration Staff on Dear Health Care Provider Letters: Improving Communication of Important Safety Information Concept Standardizing REMS programs, components and development of a potential tiered REMS System Concept 2010 National Drug Control Strategy (ONDCP)
Client expense: $240,240 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Institutes of Health (NIH), SENATE, White House Office
2010 · fourth_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298, and S. 525, S. 1232 and S. 80; In support of Medicare Part D Improvement: S. 266 and H.R. 3418; In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975 and H.R. 2417
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Pharmacy
HR 5710 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010 S 256/HR 2923 - Combat Methamphetamine Enhancement Act of 2009 S 3397/ HR 1359 - Secure and Responsible Drug Disposal Act of 2010 S 80 - Pharmaceutical Market Access Act of 2009 HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 HAMDT 740 (to HR 5822 Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2010) - a VA prescription drug re-labeling program HR 1204 - The Community Pharmacy Fairness Act of 2009 S 754 - The Methadone Treatment and Protection Act of 2009 HR 2855 - The Drug Overdose Reduction Act HR 163 - Prescription Drug Affordability Act HR 3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps (Docket Number: FDA2010N0184) Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket Number: FDA2010N0001) Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting on Opioid REMS (Docket Number: FDA2010N0168) Developing Guidance on Naming, Labeling, and Packaging Practices to Reduce Medication Errors; Public Workshop; Request for Comments (Docket Number: FDA2010N0128) Prescription Drug User Fee Act; Meetings on Reauthorization; Public Meetings (Docket Number FDA-2010-N-0284 and 2009-D-0461) Risk Evaluation and Mitigation Strategies; Notice of Public Meeting; Reopening of Comment Period (Docket Number: FDA2010N0437) Development and Distribution of Patient Medication Information for Prescription Drugs; Public Hearing (Docket Number: DEA 337N) Dispensing of Controlled Substances at Long-Term Care Facilities; Notice, Solicitation of Information (Docket Number: DEA-339S) Role of Authorized Agents in Communicating Controlled Substance Prescriptions to Pharmacies DEA National Drug Take-Back Day Concept Standardizing REMS programs, components and development of a potential tiered REMS System
Client expense: $212,859 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2010 · third_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 1232 and S. 80, In support of Medicare Part D Improvement: S. 266 and H.R. 3418, In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975 and H.R. 2417
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Comprehensive Health Care Reform. P.L. 111-148 (H.R. 3590), P.L. 111-152 (H.R. 4872): implementation of provisions relating to reducing permitted age rating ratio for insurance premiums, inclusion of patient-centered quality reporting requirements for providers, creating new claims reviews processes and provider certification, requiring reporting by practitioners of gifts received from pharmaceutical and medical device manufacturers. Importation of Prescription Drugs. H.R. 163, H.R. 1298, S. 525, S. 3415: provisions facilitating the importation of prescription drugs.
Client expense: $440,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2010 · third_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1268 and S. 525, S. 1232 and S. 80; In support of Medicare Part D Improvement: S. 266 and H.R. 3418; In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975 and H.R. 2417
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); the Pharmaceutical Market Access and Drug Safety Act (S. 525)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Pharmacy
HR 1204 - The Community Pharmacy Fairness Act of 2009 S 80 - Pharmaceutical Market Access Act of 2009 HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 SRes 539 - A resolution designating May 24, 2010, as "Prescription Drug Disposal Awareness Day S 256 - Combat Methamphetamine Enhancement Act of 2009 S 754 - The Methadone Treatment and Protection Act of 2009 HR 2855 - The Drug Overdose Reduction Act HR 163 - Prescription Drug Affordability Act HR 3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps (Docket Number: FDA2010N0184) Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket Number: FDA2010N0001) Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Docket Number: FDA-2009-N-0247) FDA Transparency Initiative: Draft Proposals for Public Comment Regarding Disclosure Policies of the U.S. Food and Drug Administration; Availability (Docket Number: FDA2010N0168) Developing Guidance on Naming, Labeling, and Packaging Practices to Reduce Medication Errors; Public Workshop; Request for Comments (Docket Number: FDA2010N0128) Prescription Drug User Fee Act; Meetings on Reauthorization; Public Meetings (Docket Number FDA2009D0461) FDA Draft Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications (Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all pharmacy-based communications (Docket Number: FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting (Docket Number: FDA-2010-N-0001) Pharmaceutical Supply Chain; Public Workshop (Docket Number: DEA-218I) Electronic Prescriptions for Controlled Substances; Final Rule (Docket Number: FDA-2009-N-0582) Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner (Docket Number: FDA-2010-N-0136) Request for Comment on Implementation of the Family Smoking Prevention and Tobacco Control Act (Docket Number: DEA-328P) Implementation of the Methamphetamine Production Prevention Act of 2008 (Docket Number: FDA2010N0001) Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Opioid REMS) (Docket Number: FDA-2010-N-0284, FDA-2009-D-0461) Risk Evaluation and Mitigation Strategies; Notice of Public Meeting (Docket Number: FDA-2009-D-0001) Guidance for Industry on Standards for Securing the Drug Supply Chain--Standardized Numerical Identification for Prescription Drug Packages; Availability ONDCPs 2010 National Drug Control Policy FDA Safe Use Initiative Concept - Reauthorization of Prescription Drug User Fee Act Concept - DEA Agent of the Prescriber Concept - Oppose Liberalizing Prescription Drug Importation
2010 · second_quarter · Health Issues
Comprehensive Health Care Reform. P.L. 111-148 (H.R. 3590), P.L. 111-152 (H.R. 4872): implementation of provisions relating to reducing permitted age rating ratio for insurance premiums, inclusion of patient-centered quality reporting requirements for providers, creating new claims reviews processes and provider certification, requiring reporting by practitioners of gifts received from pharmaceutical and medical device manufacturers. Importation of Prescription Drugs. H.R. 163, H.R. 1298, S. 525, S. 3415: provisions facilitating the importation of prescription drugs.
Client expense: $320,000 · Firm income: Not reported
2010 · second_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S.525, S. 1232, S. 80; In support of Medicare Part D Improvement: S. 266 and H.R. 3418; In support of Preventing Waste, Fraud, and Abuse in Medicare: S. 975; In support of Removing Social Security Numbers from Medicare Cards: H.R. 2417
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 1232 and S. 80, In support of Medicare Part D Improvement: S. 266 and H.R. 3418, In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975 and H.R. 2417
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Pharmacy
S 754 - The Methadone Treatment and Protection Act of 2009 HR 2855 - The Drug Overdose Reduction Act S 256 - Combat Methamphetamine Enhancement Act of 2009 HR 1706 - Protecting Consumer Access to Generic Drugs Act of 2009 HR 3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps HR 1204 - The Community Pharmacy Fairness Act of 2009 S 80 - Pharmaceutical Market Access Act of 2009 HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 163 - Prescription Drug Affordability Act (Docket Number FDA2009D0461) FDA Draft Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications (Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting on the types of communications that patients receive at the pharmacy including: medication guides; patients package inserts; and consumer medication information (Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all pharmacy-based communications (Docket Number: FDA2009N0295) Providing Effective Information to Consumers About Prescription Drug Risks and Benefits; Public Workshop (Docket Number: FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting (Docket Number: FDA2009N0247) Food and Drug Administration Transparency Task Force; Request for Comments (Docket Number: DEA321) Identification of Institution-based Individual Practitioners (Docket Number: FDA-2009-D-0001) Guidance for Industry on Standards for Securing the Drug Supply Chain--Standardized Numerical Identification for Prescription Drug Packages; Availability (Docket Number: FDA2010N0128) Prescription Drug User Fee Act; Public Meeting (Docket Number: DEA-218I) Electronic Prescriptions for Controlled Substances; Final Rule (Docket Number: FDA2004N0449) (formerly Docket Number: 2004N0439) Current Good Manufacturing Practice for Positron Emission Tomography Drugs Notice Regarding 340B Drug Pricing ProgramContract Pharmacy Services Concept - Medication Adherence Concept - Pharmacogenomics Concept - DEA Agent of the Prescriber Concept - Oppose Liberalizing Prescription Drug Importation
2010 · first_quarter · Health Issues
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Health Issues
Universal Coverage. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590: provisions providing health care or insurance for all U.S. residents and to control the cost and enhance the quality of the health care system. Importation of Prescription Drugs. H.R. 3590, H.R. 163, H.R. 1298, S. 525: provisions facilitating the importation of prescription drugs. Health Information Technology. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 1031, H.R. 1039, S. 179, S. 444: provisions facilitating the adoption of modern information technology. Generic Drugs. S. 369: provision to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. Long-Term Services and Supports. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, Senate Finance Committee Mark of Americas Healthy Futures Act: provisions providing assistance to individuals with functional impairments maintain their independence, authorizing establishment of a community living infrastructure, and providing assistance to family caregivers (CLASS Act). Healthcare Workforce. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 468, S. 245, S. 750, H.R. 3098: provisions relating to the recruitment, training, and support of health care professionals and direct care workers in support of older Americans. Affordability of Health Coverage for Seniors. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 3962, S.1679: provisions reducing allowable age rating ratio for health insurance premiums.
Client expense: $350,000 · Firm income: Not reported
2010 · first_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525, S. 80 and S. 1232; In support of Medicare Part D Improvement: S. 266 and H.R. 3418; In support of Preventing Waste, Fraud, and Abuse in Medicare: S. 975
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525, S. 80 and S. 1232; In support of Medicare Part D Improvement: S. 266 and H.R. 3418; In support of Preventing Waste, Fraud, and Abuse in Medicare: S. 975
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 1232 and S. 80, In support of Medicare Part D Improvement: S. 266 and H.R. 3418, In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $6,200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · third_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act
Client expense: $5,490,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · first_quarter · Consumer Issues/Safety/Products
S.80, Pharmaceutic Market Access Act, 1/09 HR 91, Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 HR 163, The Prescription Drug Affordability Act, 1/09 S. 501, Fair prescription Drug Competition Act, 3/09 S. 767, Independent Drug Education and Outreach Act, 4/09 HR 573, Act to Prohibit the Marketing of Authorized Generic Drugs, 1/09 HR 1427, Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 HR 1548, Pathway for Biosimilars Act, 3/09 HR 759, The Food, drug and Cosmetic Globalization Act, 1/09
Client expense: $5,860,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · fourth_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $5,590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · fourth_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $5,590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · fourth_quarter · Pharmacy
S 754 - The Methadone Treatment and Protection Act of 2009 HR 2855 - The Drug Overdose Reduction Act S 256 - Combat Methamphetamine Enhancement Act of 2009 HR 1706 - Protecting Consumer Access to Generic Drugs Act of 2009 HR 3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps HR 1204 - The Community Pharmacy Fairness Act of 2009 S 80 - Pharmaceutical Market Access Act of 2009 HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 163 - Prescription Drug Affordability Act (Docket Number FDA2009D0461) FDA Draft Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications (Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting on the types of communications that patients receive at the pharmacy including: medication guides; patients package inserts; and consumer medication information (Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all pharmacy-based communications (Docket Number FDA2009D0181) Draft Guidance for Industry on Label Comprehension Studies for Nonprescription Drug Products; Availability (Docket Number FDA2009N0295) Providing Effective Information to Consumers About Prescription Drug Risks and Benefits; Public Workshop (Docket Number FDA1977N0013) (formerly Docket No. 1977N0094L) Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph (Docket Number FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting (Docket Number FDA2006N0238) (formerly Docket No. 2006N0062) Expanded Access to Investigational Drugs for Treatment Use (Docket Number FDA2006N0237) (formerly Docket No. 2006N0061) Charging for Investigational Drugs Under an Investigational New Drug Application (Docket Number FDA2009N0247) Food and Drug Administration Transparency Task Force; Reopening of Comment Period (Docket Number DEA321) Identification of Institution-based Individual Practitioners (Docket Number FDA2009N0374) Educating the Public About Removal of Essential-Use Designation for Epinephrine; Public Workshop; Request for Comments (Docket Number FDA2009N0441) Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing (Docket Number FDA-2009-N-0138) Liver Injury Related to the Use of Acetaminophen; Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee and the Anesthetic and Life Support Drugs Advisory Committee (DEA Information Collection 1117-0046) Self-Certification, Training and Logbooks for Regulated Sellers of Scheduled Listed Chemical Products (Docket Number FDA2008N0424) Postmarketing Safety Reporting for Combination Products (Docket Number FDA2009N0664) Risk Communication Advisory Committee; Notice of Meeting Concept - Medication Adherence Concept - Pharmacogenomics Concept - Oppose Liberalizing Prescription Drug Importation Concept - Agent of the Prescriber
2009 · fourth_quarter · Health Issues
Universal Coverage. H.R. 3590, H.R. 3962, H.R.15, H.R.193, H.R. 676, H.R.1200, S. 4: provisions providing health care or insurance for all U.S. residents and to control the cost and enhance the quality of the health care system. Importation of Prescription Drugs. H.R. 3590, H.R. 163, H.R. 1298, S. 525: provisions facilitating the importation of prescription drugs. Health Information Technology. H.R. 1031, H.R. 1039, S. 179, S. 444: provisions facilitating the adoption of modern information technology. Generic Drugs. S. 369: provision to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. Long-Term Services and Supports. H.R. 3590, H.R. 3962, S. 697/H.R.1721, H.R. 3200, S. 1679, Senate Finance Committee Mark of Americas Healthy Futures Act: provisions providing assistance to individuals with functional impairments maintain their independence, authorizing establishment of a community living infrastructure, and providing assistance to family caregivers (CLASS Act). Healthcare Workforce. H.R. 3590, H.R. 3962, H.R. 468/S. 245, S. 750, H.R. 3098: provisions relating to the recruitment, training, and support of health care professionals and direct care workers in support of older Americans. Affordability of Health Coverage for Seniors. H.R. 3590, H.R. 3962, S.1679: provisions reducing allowable age rating ratio for health insurance premiums.
Client expense: $340,000 · Firm income: Not reported
2009 · fourth_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 1232 and S. 80 and S. Amdt. 2793, In support of Medicare Part D Improvement: S. 266 and H.R. 3418, In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 80 and S. 1232 and S. Amdt. 2793; In support of Medicare Part D Improvement: S. 266 and H.R. 3418; In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Health Issues
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act
Client expense: $5,420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · first_quarter · Consumer Issues/Safety/Products
S.80, Pharmaceutic Market Access Act, 1/09 HR 91, Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 HR 163, The Prescription Drug Affordability Act, 1/09 S. 501, Fair prescription Drug Competition Act, 3/09 S. 767, Independent Drug Education and Outreach Act, 4/09 HR 573, Act to Prohibit the Marketing of Authorized Generic Drugs, 1/09 HR 1427, Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 HR 1548, Pathway for Biosimilars Act, 3/09 HR 759, The Food, drug and Cosmetic Globalization Act, 1/09
Client expense: $5,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · third_quarter · Pharmacy
HR1204 - The Community Pharmacy Fairness Act of 2009 S80 - Pharmaceutical Market Access Act of 2009 HR1298/S525 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR163 - Prescription Drug Affordability Act HR2400 - Strategies to Address Antimicrobial Resistance Act HR1706 - Protecting Consumer Access to Generic Drugs Act of 2009 HR3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps (Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all Pharmacy-Based Communications (Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting on the types of communications that patients receive at the pharmacy includes: medication guides; patients package inserts; and consumer medication information (Docket Number FDA2009D0181) Draft Guidance for Industry on Label Comprehension Studies for Nonprescription Drug Products;Availability (Docket Number FDA2009N0295) Providing Effective Information to Consumers About Prescription Drug Risks and Benefits; Public Workshop (Docket Number FDA1977N0013) (formerly Docket No. 1977N0094L) Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph (Docket Number FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting (Docket Number FDA2006N0238) (formerly Docket No. 2006N0062) Expanded Access to Investigational Drugs for Treatment Use (Docket Number FDA2006N0237) (formerly Docket No. 2006N0061) Charging for Investigational Drugs Under an Investigational New Drug Application (Docket Number FDA2009N0247) Food and Drug Administration Transparency Task Force; Reopening of Comment Period (Docket Number DEA321a) Identification of Institution-based Individual Practitioners (Docket Number FDA2009N0374) Educating the Public About Removal of Essential-Use Designation for Epinephrine; Public Workshop; Request for Comments (Docket Number FDA2009N0441) Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing (Docket Number FDA-2009-N-0138) Liver Injury Related to the Use of Acetaminophen; Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee and the Anesthetic and Life Support Drugs Advisory Committee (DEA Information Collection 1117-0046) Self-Certification, Training and Logbooks for Regulated Sellers of Scheduled Listed Chemical Products Concept - Oppose Liberalizing Prescription Drug Importation Concept - Misuse of Antibiotics in Agriculture
2009 · third_quarter · Health Issues
Universal Coverage. H.R.15, H.R.193, H.R. 676, H.R.1200, S. 4: provisions providing health care or insurance for all U.S. residents and to control the cost and enhance the quality of the health care system. Importation of Prescription Drugs. H.R. 163, H.R. 1298, S. 525: provisions facilitating the importation of prescription drugs. Health Information Technology. H.R. 1031, H.R. 1039, S. 179, S. 444: provisions facilitating the adoption of modern information technology. Generic Drugs. S. 369: provision to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. Long-Term Services and Supports. S. 697/H.R.1721, H.R. 3200, S. 1679, Senate Finance Committee Mark of Americas Healthy Futures Act: provisions providing assistance to individuals with functional impairments maintain their independence, authorizing establishment of a community living infrastructure, and providing assistance to family caregivers (CLASS Act). Healthcare Workforce. H.R. 468/S. 245, S. 750, H.R. 3098: provisions relating to the recruitment, training, and support of health care professionals and direct care workers in support of older Americans. Affordability of Health Coverage for Seniors. S.1679: provisions reducing allowable age rating ratio for health insurance premiums.
Client expense: $340,000 · Firm income: Not reported
2009 · third_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 1232 and S. 80, In support of Medicare Part D Improvement: S. 266 and H.R. 3418, In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975
Client expense: $42,520 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 80 and S. 1232; In support of Medicare Part D Improvement: S. 266 and H.R. 3418; In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Health Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); The Pharmaceutical Market Access and Drug Safety Act (S.525)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Consumer Issues/Safety/Products
S.80, Pharmaceutic Market Access Act, 1/09 HR 91, Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 HR 163, The Prescription Drug Affordability Act, 1/09 S. 501, Fair prescription Drug Competition Act, 3/09 S. 767, Independent Drug Education and Outreach Act, 4/09 HR 573, Act to Prohibit the Marketing of Authorized Generic Drugs, 1/09 HR 1427, Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 HR 1548, Pathway for Biosimilars Act, 3/09 HR 759, The Food, drug and Cosmetic Globalization Act, 1/09
Client expense: $5,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · second_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutic Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act
Client expense: $5,580,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · second_quarter · Pharmacy
HR1204 - The Community Pharmacy Fairness Act of 2009 S80 - Pharmaceutical Market Access Act of 2009 S525/HR1298 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR163 - Prescription Drug Affordability Act HR2400 - Strategies to Address Antimicrobial Resistance Act HR1706 - Protecting Consumer Access to Generic Drugs Act of 2009 (Docket No. DEA322I) Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (Docket No. FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting (Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all Pharmacy-Based Communications (Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting (focused on the types of communications that patients receive at the pharmacy includes: medication guides; patients package inserts; and consumer medication information) (Docket Number: FDA2009D0001) Draft Guidance for Industry on Standards for Securing the Drug Supply ChainStandardized Numerical Identification for Prescription Drug Packages; Availability (Docket Number: FDA-2008-S-0627) Expert and Consumer Evaluation of Consumer Medication Information -- 2008 (Docket No. FDA1977N0013) (formerly Docket No. 1977N0094L) Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph (Docket No. FDA2009D0181) Draft Guidance for Industry on Label Comprehension Studies for Nonprescription Drug Products; Availability (Docket No. FDA2009N0138) Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee; Notice of Meeting
Client expense: $194,415 · Firm income: Not reported
2009 · second_quarter · Health Issues
Universal Coverage. H.R. 15, H.R. 193, H.R. 676, H.R. 1200, S. 4: provisions providing health care or insurance for all U.S. residents and to control the cost and enhance the quality of the health care system. Importation of Prescription Drugs. H.R. 163, H.R. 1298, S. 525: provisions facilitating the importation of prescription drugs. Health Information Technology. H.R. 1031, H.R. 1039, S. 179, S. 444: provisions facilitating the adoption of modern information technology. Generic Drugs. S. 369: provision to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. Long-Term Services and Supports. S. 697/H.R.1721: provisions providing assistance to individuals with functional impairments maintain their independence, authorizing establishment of a community living infrastructure, and providing assistance to family caregivers (CLASS Act). Healthcare Workforce. H.R. 468/S. 245, S. 750, H.R. 3098: provisions relating to the recruitment, training, and support of health care professionals and direct care workers in support of older Americans.
Client expense: $300,000 · Firm income: Not reported
2009 · second_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 1232 and S. 80, In support of Medicare Part D Improvement: S. 266, In support of Preventing Waste, Fraud and Abuse in Medicare: S. 975
Client expense: $44,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); The Pharmaceutical Market Access and Drug Safety Act (S.525)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Pharmacy
HR1204 - The Community Pharmacy Fairness Act of 2009 S80 - Pharmacautical Market Access Act of 2009 S525/ HR1298 - Pharmacautical Market Access and Drug Safety Act of 2009 HR163 - Prescription Drug Affordability Act (Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all Pharmacy-Based Communications (Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting (focused on the types of communications that patientss receive at the pharmacy includes: medication guides; patients package inserts; and consumer medication information. (Docket Number: FDA2009D0001) Draft Guidance for Industry on Standards for Securing the Drug Supply ChainStandardized Numerical Identification for Prescription Drug Packages; Availability (Docket Number: FDA-2008-S-0627) Expert and Consumer Evaluation of Consumer Medication Information -- 2008 (Docket Number DoD2008HA0029; 0720AB22) Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/ TRICARE: Inclusion of TRICARE Retail Pharmacy Program in Federal Procurement of Pharmaceuticals (Request for Information (RFI): HHS-FDA-RFI-09-002 (Special Notice)) FDA Sentinel Initiative Concept (No Language) FDA Risk Evaluation and Mitigation Strategies (REMS) for Opioid Anagesic Medications
Client expense: $182,592 · Firm income: Not reported
2009 · first_quarter · Consumer Issues/Safety/Products
S.80, Pharmaceutic Market Access Act, 1/09 HR 91, Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 HR 163, The Prescription Drug Affordability Act, 1/09 S. 501, Fair prescription Drug Competition Act, 3/09 S. 767, Independent Drug Education and Outreach Act, 4/09 HR 573, Act to Prohibit the Marketing of Authorized Generic Drugs, 1/09 HR 1427, Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 HR 1548, Pathway for Biosimilars Act, 3/09 HR 759, The Food, drug and Cosmetic Globalization Act, 1/09
Client expense: $6,140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · first_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 163 and H.R. 1298 and S. 525 and S. 80, In support of Medicare Part D Improvement: S. 266
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General Healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); and The Pharmaceutical Market Access and Drug Safety Act (S.525)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
Universal Coverage. H.R. 15, H.R. 193, H.R. 676, H.R. 1200, S. 4: provisions providing health care or insurance for all U.S. residents and to control the cost and enhance the quality of the health care system. Importation of Prescription Drugs. H.R. 163, H.R. 1298, S. 525: provisions facilitating the importation of prescription drugs. Health Information Technology. H.R. 1031, H.R. 1039, S. 179, S. 444: provisions facilitating the adoption of modern information technology. Generic Drugs. S. 369: provision to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. Long-Term Services and Supports. S. 697, H.R.1721: provisions providing assistance to individuals with functional impairments maintain their independence, authorizing establishment of a community living infrastructure, and providing assistance to family caregivers (CLASS Act). Healthcare Workforce. H.R. 468, S. 245, S. 750: provisions relating to the recruitment, training, and support of health care professionals and direct care workers in support of older Americans.
Client expense: $290,000 · Firm income: Not reported
Client expense: $151,510 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $149,615 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $117,517 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Client expense: $157,696 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Indian Health Service, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE